Intravitreal bevacizumab has initial clinical benefit lasting eight weeks in eyes with neovascular age-related macular degeneration.
| Image |  |
|---|---|
| Description | scientific article published on December 2008 |
| Author/s |
author: David N. Zacks |
| Publication date | December 1, 2008 |
| Language | English |
| Country of origin | |
| Wikipedia link | |
| Copyright status | |
| Missing/wrong data? | Edit Wikidata item |